By Fineline Cube Huadong Medicine Co., Ltd. (SHE: 000963) announced it has received clinical trial approval from China’s National Medical Products Administration (NMPA) for HDM2017, an antibody drug conjugate (ADC) targeting Cadherin 17 (LI-cadherin). The drug will be evaluated in combination with fruquintinib for the treatment of advanced colorectal cancer (CRC).
Regulatory Milestones & Development Timeline
| Milestone | Date | Jurisdiction |
|---|---|---|
| Advanced Solid Tumors Trial Clearance | September 2025 | China & US |
| Orphan Drug Designation | March 2026 | US FDA |
| NMPA Clinical Trial Approval | May 2026 | China |
| Indications for Orphan Status | Biliary tract cancer, gastric cancer, pancreatic cancer | US FDA |
Drug Profile & Preclinical Data
- Molecule: Antibody drug conjugate (ADC) targeting Cadherin 17 (LI-cadherin)
- Mechanism: Selective targeting of CDH17-positive tumor cells with cytotoxic payload delivery
- Preclinical Efficacy: Demonstrated potent anti-tumor effects in CDH17-positive models of:
- Colorectal cancer
- Pancreatic cancer
- Gastric cancer
- Safety Profile: Showed favorable druggability, safety, and tolerability in animal studies
- Combination Strategy: Will be assessed with fruquintinib, Huadong’s approved anti-angiogenic therapy
Strategic Significance & Market Opportunity
This NMPA approval represents a critical advancement in Huadong’s oncology pipeline, leveraging the company’s expertise in both targeted therapies and combination approaches. The triple orphan drug designation from the US FDA underscores the high unmet medical need in biliary tract, gastric, and pancreatic cancers.
Colorectal Cancer Context:
- Advanced CRC remains challenging to treat with limited options after first-line therapy failure
- The combination of an ADC targeting tumor-specific antigens with anti-angiogenic therapy represents a novel approach
- CDH17 expression provides a potential biomarker for patient selection
Competitive Landscape & Commercial Outlook
- ADC Market: Rapidly expanding therapeutic class with multiple recent approvals across solid tumors
- Differentiation: HDM2017’s targeting of Cadherin 17 offers a unique mechanism compared to established ADC targets
- Global Strategy: Dual regulatory pathway in China and US positions the asset for potential international development
- Pipeline Synergy: Combination with fruquintinib leverages Huadong’s existing commercial infrastructure and clinical experience
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical development timelines, regulatory approvals, and therapeutic potential of HDM2017. Actual results may differ due to risks including clinical trial outcomes, regulatory requirements, competitive dynamics, and market conditions.-Fineline Info & Tech